BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 16429647)

  • 1. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
    Fergelot P; Rioux-Leclercq N; Patard JJ
    Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis: the renal cancer model].
    Méjean A; Lebret T
    Prog Urol; 2008 Nov; 18 Suppl 7():S309-14. PubMed ID: 19070808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of vascular endothelial growth factor in kidney and prostate cancer.
    Delongchamps NB; Peyromaure M
    Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
    Choueiri TK; Bukowski RM; Rini BI
    Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
    Kim WY; Kaelin WG
    Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis.
    Okoń K
    Pol J Pathol; 2008; 59(3):129-76. PubMed ID: 19097356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
    Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
    Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
    Keedy VL; Sandler AB
    Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell cancer.
    Hutson TE; Figlin RA
    Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
    Ghezala W; Lefi M; Touffahi M; Saïdi R; Farhane S; Saad H
    Prog Urol; 2006 Apr; 16(2):225. PubMed ID: 16734253
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinase inhibitors in the treatment of renal cell carcinoma.
    Larkin JM; Eisen T
    Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.